Ascendis Pharma A/S
ASND
Rangering i aksjer
#1449
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Aksjekurs
$238.30
Sist synkronisert: 2026-10-21
Markedsverdi
$14.86B
Endring (1 dag)
1.69%
Endring (1 år)
17.56%
Land
DK
Handel Ascendis Pharma A/S (ASND)
Kategori
Healthcare
Aksjeprishistorikk for Ascendis Pharma A/S (ASND)
Høyeste sluttskurs: $228.08 den 2026-10-01
Laveste sluttskurs: $19.55 den 2015-01-01
Laveste sluttskurs: $19.55 den 2015-01-01
Aksjeprishistorikk for Ascendis Pharma A/S fra 2015 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 11.08% |
| 2025 | 53.71% |
| 2024 | 15.66% |
| 2023 | -2.60% |
| 2022 | -12.93% |
| 2021 | -20.35% |
| 2020 | 42.79% |
| 2019 | 94.20% |
| 2018 | 63.66% |
| 2017 | 87.65% |
| 2016 | 15.96% |
| 2015 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $755.78 | 7.42% |
CH
|
